Ayush Chordia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayush Chordia has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Krishna Deshmukh
Department of Geriatric Medicine, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, India
2 shared publications - Mohammad Arfat Ganiyani
Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA
2 shared publications Abdus Samad Momin
Department of Pediatrics, Grant Government Medical College and Sir JJ Group of Hospitals, Byculla, Mumbai, Maharashtra, India
1 shared publication- Aditya Shah
Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic , Rochester, MN
1 shared publication - Ajit Bhagwat
Department of Pediatrics, Grant Government Medical College and Sir JJ Group of Hospitals, Byculla, Mumbai, Maharashtra, India
1 shared publication - Alan Johnson
Department of Pediatrics, Grant Government Medical College and Sir JJ Group of Hospitals, Byculla, Mumbai, Maharashtra, India
1 shared publication
Latest Publications
- Open Access
- 10 April 2023
- Published by Gavin Publishers in International Journal of Geriatrics and Gerontology
- Vol. 6 (1)
Managing Cognitive Dysfunction in Geriatric Populations: A Multidisciplinary Approach
Cognitive dysfunction disorders, such as Alzheimer’s disease and other forms of dementia, are prevalent among the geriatric population. The management of cognitive dysfunction disorders requires a multidisciplinary approach that includes pharmacological and non-pharmacological interventions. This article provides an overview of recent management approaches for geriatric populations suffering from cognitive dysfunction disorders. Pharmacological management includes the use of cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists to improve cognitive function and delay disease progression. Non-pharmacological management includes cognitive stimulation therapy, physical activity, and social engagement to improve cognitive function and maintain quality of life. Occupational therapy and speech therapy can address functional impairments and communication difficulties associated with cognitive dysfunction disorders. Clinical trials to evaluate the effect and the safety of caregiver support can also play a significant role in laying down new strategies. Emerging therapies, such as immunotherapy, gene therapy, and stem cell therapy, hold promise for disease modification and prevention. However, these therapies are still in the early stages of development and require further research and. Overall, the management of cognitive dysfunction disorders in geriatric populations requires a personalized approach that considers the individual needs and preferences of each individual. Collaborative care models that involve patients, caregivers, and healthcare providers can promote effective disease management and improve patient outcomes. Future research should focus on identifying new therapeutic targets and interventions to prevent and treat cognitive dysfunction disorders in geriatric populations.
- 10 April 2023
- Published by Gavin Publishers in International Journal of Geriatrics and Gerontology
- Vol. 6 (1)
Open AccessManaging Cognitive Dysfunction in Geriatric Populations: A Multidisciplinary Approach
Cognitive dysfunction disorders, such as Alzheimer’s disease and other forms of dementia, are prevalent among the geriatric population. The management of cognitive dysfunction disorders requires a multidisciplinary approach that includes pharmacological and non-pharmacological interventions. This article provides an overview of recent management approaches for geriatric populations suffering from cognitive dysfunction disorders. Pharmacological management includes the use of cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists to improve cognitive function and delay disease progression. Non-pharmacological management includes cognitive stimulation therapy, physical activity, and social engagement to improve cognitive function and maintain quality of life. Occupational therapy and speech therapy can address functional impairments and communication difficulties associated with cognitive dysfunction disorders. Clinical trials to evaluate the effect and the safety of caregiver support can also play a significant role in laying down new strategies. Emerging therapies, such as immunotherapy, gene therapy, and stem cell therapy, hold promise for disease modification and prevention. However, these therapies are still in the early stages of development and require further research and. Overall, the management of cognitive dysfunction disorders in geriatric populations requires a personalized approach that considers the individual needs and preferences of each individual. Collaborative care models that involve patients, caregivers, and healthcare providers can promote effective disease management and improve patient outcomes. Future research should focus on identifying new therapeutic targets and interventions to prevent and treat cognitive dysfunction disorders in geriatric populations.
- Open Access
Have the COVID-19 pandemic and lockdown affected children’s mental health in the long term? A repeated cross-sectional study
Objective: The study aimed to evaluate the impact of the COVID-19 pandemic on levels of anxiety and depressive symptoms in children and adolescents. Design: Cross-sectional surveys were carried out on the mental health of children; one survey was conducted before the COVID-19 pandemic and one into the pandemic, 15 months after the school closures and implementation of lockdown and social distancing. Demographic data and COVID-19 pandemic-related data were collected from specific parent-report and self-report questionnaires. Participants: Participants included children and adolescents between ages 6 and 16 years, attending a tertiary care hospital without any diagnosed major psychiatric or chronic disorder. Analysis: Data were collected at two points (before the COVID-19 pandemic and during it) and compared. Levels of anxiety and depressive symptoms were compared and tested for statistically significant differences between these two points using appropriate statistical tests. Regression models were constructed to predict the factors affecting increased anxiety levels and depressive symptoms in the COVID-19 period. Results: 832 and 1255 children/adolescents were included in the study during the pre-COVID-19 and COVID-19 times, respectively. The median age of the participants was 10 years (IQR=4 years). The median (IQR) Spence Children’s Anxiety Scale score was 24 (12) at the pre-COVID-19 point and 31 (13) during the COVID-19 pandemic (pc =−0.063). Regression analysis showed that many factors, including the duration of smartphone use, female gender and only child status, were associated with increased anxiety or depression levels. Conclusion: A large proportion of children had elevated anxiety and depressive symptoms during the pandemic relative to before the pandemic, suggesting a need for measures to engage children in healthy habits to protect children’s mental health and continuous monitoring of children during such scenarios.
Open AccessHave the COVID-19 pandemic and lockdown affected children’s mental health in the long term? A repeated cross-sectional study
Objective: The study aimed to evaluate the impact of the COVID-19 pandemic on levels of anxiety and depressive symptoms in children and adolescents. Design: Cross-sectional surveys were carried out on the mental health of children; one survey was conducted before the COVID-19 pandemic and one into the pandemic, 15 months after the school closures and implementation of lockdown and social distancing. Demographic data and COVID-19 pandemic-related data were collected from specific parent-report and self-report questionnaires. Participants: Participants included children and adolescents between ages 6 and 16 years, attending a tertiary care hospital without any diagnosed major psychiatric or chronic disorder. Analysis: Data were collected at two points (before the COVID-19 pandemic and during it) and compared. Levels of anxiety and depressive symptoms were compared and tested for statistically significant differences between these two points using appropriate statistical tests. Regression models were constructed to predict the factors affecting increased anxiety levels and depressive symptoms in the COVID-19 period. Results: 832 and 1255 children/adolescents were included in the study during the pre-COVID-19 and COVID-19 times, respectively. The median age of the participants was 10 years (IQR=4 years). The median (IQR) Spence Children’s Anxiety Scale score was 24 (12) at the pre-COVID-19 point and 31 (13) during the COVID-19 pandemic (pc =−0.063). Regression analysis showed that many factors, including the duration of smartphone use, female gender and only child status, were associated with increased anxiety or depression levels. Conclusion: A large proportion of children had elevated anxiety and depressive symptoms during the pandemic relative to before the pandemic, suggesting a need for measures to engage children in healthy habits to protect children’s mental health and continuous monitoring of children during such scenarios.